Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Disparities in antiretroviral treatment: a comparison of behaviorally HIV-infected youth and adults in the HIV Research Network.

Agwu AL, Fleishman JA, Korthuis PT, Siberry GK, Ellen JM, Gaur AH, Rutstein R, Gebo KA; HIV Research Network..

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):100-7. doi: 10.1097/QAI.0b013e31822327df.

2.

Predictors of highly active antiretroviral therapy utilization for behaviorally HIV-1-infected youth: impact of adult versus pediatric clinical care site.

Agwu AL, Siberry GK, Ellen J, Fleishman JA, Rutstein R, Gaur AH, Korthuis PT, Warford R, Spector SA, Gebo KA.

J Adolesc Health. 2012 May;50(5):471-7. doi: 10.1016/j.jadohealth.2011.09.001. Epub 2011 Nov 4.

3.
4.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.

PMID:
20238364
5.

Definition of advanced age in HIV infection: looking for an age cut-off.

Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, Pulido F, Asensi V, del Amo J, Moreno S; CoRIS..

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1000-6. doi: 10.1089/AID.2011.0377.

6.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
7.

Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.

Lazarus JR, Rutstein RM, Lowenthal ED.

HIV Med. 2015 Jul;16(6):355-61. doi: 10.1111/hiv.12220. Epub 2015 Jan 21.

8.

Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy.

Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, Gillini L, Zinzi D, De Luca A, Antinori A, Ippolito G.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):326-31.

PMID:
11317073
9.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD..

PLoS One. 2006 Dec 20;1:e89.

10.

Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.

Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM.

Clin Infect Dis. 2007 Dec 15;45(12):1633-9. doi: 10.1086/523729.

PMID:
18190326
11.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.

12.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team..

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
13.

Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response.

Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Barkanic G, Raffanti SP, Sterling TR.

PLoS One. 2009 Sep 9;4(9):e6961. doi: 10.1371/journal.pone.0006961.

14.

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network (G03/103)..

Arch Intern Med. 2005 Jul 11;165(13):1533-40.

PMID:
16009870
15.

Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.

Kuyper LM, Wood E, Montaner JS, Yip B, O'connell JM, Hogg RS.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1470-6.

PMID:
15602125
16.

Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; Pediatric AIDS Clinical Trials Group 381 Study Team..

AIDS Patient Care STDS. 2008 Jul;22(7):545-52. doi: 10.1089/apc.2007.0200.

17.

One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.

Park WB, Choe PG, Kim SH, Jo JH, Bang JH, Kim HB, Kim NJ, Oh M, Choe KW.

J Intern Med. 2007 Mar;261(3):268-75.

18.
19.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network..

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337
20.

Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.

Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kaboré I, Sanou MJ, Greenwell F, Soudré R, Sondo B.

AIDS Care. 2012;24(4):478-90. doi: 10.1080/09540121.2011.630353. Epub 2011 Dec 7.

PMID:
22148973

Supplemental Content

Support Center